Retatrutide is a triple-receptor agonist that activates GLP-1, GIP, and glucagon simultaneously—producing 28.7% mean weight loss in Phase 3 trials, the largest result ever recorded in obesity pharmacotherapy. It differs from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) by adding glucagon receptor activation, which drives energy expenditure and hepatic fat oxidation—mechanisms neither semaglutide nor tirzepatide can replicate. As of May 2026, retatrutide has not received UK MHRA approval and is not available on prescription. This guide covers the clinical trial data, mechanism of action, safety signals from TRIUMPH-4, the regulatory timeline, and where research-grade retatrutide fits in the UK market.
Key Takeaways
- Retatrutide is a triple agonist: GLP-1 + GIP + glucagon receptors—the first compound in this class to reach Phase 3 clinical trials
- Phase 3 TRIUMPH-4 (December 2025): 28.7% mean body weight reduction at 68 weeks on 12 mg—the largest weight loss result in any obesity pharmacotherapy trial
- Glucagon receptor activation is the key differentiator—it increases energy expenditure and promotes hepatic fat oxidation (up to 82% liver fat reduction), mechanisms not present in semaglutide or tirzepatide
- New safety signal in TRIUMPH-4: dysesthesia (abnormal skin sensation) in 8.8% at 9 mg and 20.9% at 12 mg vs 0.7% on placebo—not seen with semaglutide or tirzepatide
- UK regulatory status: Not MHRA approved. Not available on NHS or private prescription. Realistic availability: 2028 at the earliest
Research-Grade Retatrutide for In Vitro Studies
Phase 3 clinical strength. Batch-specific COA. HPLC purity verified. For laboratory research use.
Browse Retatrutide →What Is Retatrutide? Triple-Receptor Mechanism Explained
Retatrutide (LY3437943) is an investigational injectable compound developed by Eli Lilly. Its defining feature: simultaneous activation of three hormone receptors that no approved obesity medicine targets together.
To understand why this matters, consider the progression: Semaglutide (Wegovy, approved 2021) activates one receptor—GLP-1. Tirzepatide (Mounjaro, approved 2022) activates two—GLP-1 and GIP. Retatrutide activates three—GLP-1, GIP, and glucagon. The clinical results follow this pattern: semaglutide produces approximately 15-20% weight loss. Tirzepatide produces approximately 22.5%. Retatrutide produces 28.7%.
Alex had been on semaglutide for 14 months—lost 11% of his bodyweight, then stalled. His clinic offered tirzepatide as the next step. He wanted to understand what was actually different about the mechanism before switching. He found the NEJM Phase 2 retatrutide paper and read it cover to cover. Not because he could access retatrutide on prescription—he couldn't—but because understanding the progression from single to dual to triple receptor agonism helped him understand what each compound was actually doing metabolically.
Retatrutide vs Semaglutide vs Tirzepatide: Direct Comparison
Note: No head-to-head trial has been published. Comparisons below are drawn from separate trials with different populations, study durations, and endpoints.
| Semaglutide (Wegovy) | Tirzepatide (Mounjaro) | Retatrutide | |
|---|---|---|---|
| Receptors targeted | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| UK approval status | MHRA approved | MHRA approved | Not approved—Phase 3 ongoing |
| Phase 2 weight loss | ~15% at 68 weeks (STEP 1) | ~22.5% at 72 weeks (SURMOUNT-1) | 24.2% at 48 weeks (NEJM, 2023) |
| Phase 3 weight loss | ~20.7% at 72 weeks | ~22.5% at 72 weeks | 28.7% at 68 weeks (TRIUMPH-4) |
| Liver fat reduction | Moderate (via weight loss) | Greater than semaglutide | Up to 82% (Phase 2a) |
| New safety signal | Thyroid C-cell tumours (rodent data) | Thyroid C-cell tumours (class effect) | Dysesthesia (8.8-20.9% at higher doses) |
Triple-Agonist Research Compounds in Stock
Retatrutide, semaglutide, tirzepatide—all available as research chemicals with independent purity verification.
Shop the Full Range →How Retatrutide Works: GLP-1, GIP, and Glucagon Receptor Activation
Retatrutide's defining feature is that it activates all three hormone receptor systems simultaneously. Each contributes differently to the metabolic outcomes observed in trials.
GLP-1 Receptor Agonism
GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted from intestinal L-cells after meals. GLP-1 receptor activation: stimulates glucose-dependent insulin secretion; suppresses glucagon release; slows gastric emptying, prolonging fullness; and acts centrally on the hypothalamus to reduce appetite. In retatrutide, the GLP-1 component provides appetite suppression and insulin-sensitising effects, though with somewhat lower potency than semaglutide alone—a deliberate design choice balancing efficacy across three pathways.
GIP Receptor Agonism
GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion in a glucose-dependent manner and influences fat metabolism in adipose tissue. Retatrutide demonstrates higher GIP receptor potency than either semaglutide (zero GIP activity) or tirzepatide. This enhanced GIP component is one proposed explanation for why retatrutide's weight loss results exceed tirzepatide's.
Glucagon Receptor Agonism: The Key Differentiator
This is the pathway that separates retatrutide from every approved obesity medicine. No currently approved therapy activates the glucagon receptor. When glucagon receptor agonism combines with GLP-1 agonism, the insulin-stimulating effects of GLP-1 counterbalance the glucose-raising effects of glucagon—the net glycaemic result is neutral or positive. The other effects of glucagon remain metabolically significant:
- Increased energy expenditure: Glucagon promotes thermogenesis in brown adipose tissue and increases basal metabolic rate—the body burns more calories at rest
- Hepatic fat oxidation: Glucagon stimulates the liver to oxidise stored fat. In Phase 2 trials, retatrutide reduced liver fat by up to 82% at 48 weeks—substantially exceeding semaglutide
- Lipolysis in adipose tissue: Glucagon reduces lipogenesis and induces lipolysis, increasing fatty acid release for energy
- LDL cholesterol reduction: Phase 2 data showed approximately 20% reductions in LDL cholesterol, possibly linked to glucagon's effect on PCSK9 degradation
Retatrutide Phase 3 Clinical Trial Results
TRIUMPH-4: The First Phase 3 Result (December 2025)
TRIUMPH-4 enrolled 445 adults with obesity or overweight and knee osteoarthritis, without diabetes. Duration: 68 weeks.
- 12 mg dose: 28.7% mean body weight reduction (placebo-adjusted: 26.6%)—the largest result recorded in any obesity pharmacotherapy trial
- Average absolute weight loss: approximately 32.3 kg (71.2 lbs) in the highest dose group
- Significant reductions in knee pain: more than 1 in 8 participants became completely free of knee pain by trial end
- Meaningful improvements in non-HDL cholesterol, CRP, triglycerides, and systolic blood pressure (reduced 14.0 mmHg)
Dysesthesia Safety Signal: What TRIUMPH-4 Revealed
New safety signal: Dysesthesia (abnormal skin sensation/tingling) in 8.8% at 9 mg and 20.9% at 12 mg vs 0.7% on placebo—not previously observed with semaglutide or tirzepatide.
The dysesthesia signal requires investigation. Its mechanism is not established, and further characterisation across remaining TRIUMPH trials will be essential before regulators can assess its significance. It is a genuine safety question that did not exist for semaglutide or tirzepatide at approval.
David, a sports medicine researcher in Edinburgh, had been watching the TRIUMPH programme since the Phase 2 NEJM paper. When TRIUMPH-4 reported in December 2025—28.7% weight loss, knee pain data, and the new dysesthesia signal all at once—his first reaction was that dysesthesia was the most important finding in the whole data package. Not because it invalidated retatrutide, but because it was a genuine unknown. He wanted to understand the mechanism before forming a view. That's the right response to new safety data.
Beyond Weight Loss: Liver Disease, Joints, and Cardiovascular Outcomes
Liver Disease (MASH/MASLD)
MASH is a progressive liver condition in a substantial proportion of people with obesity and type 2 diabetes. It can advance to cirrhosis and liver failure. No pharmacological treatment is currently approved for MASH in the UK. The Phase 2a data showing up to 82% liver fat reduction positions retatrutide as potentially the most effective pharmacological intervention in this space. The REDEFINE Phase 3 trial is examining this.
Osteoarthritis
TRIUMPH-4's knee pain reduction is notable. Pain reduction occurred faster than weight loss alone would explain, suggesting potential direct anti-inflammatory effects—whether from GLP-1's known properties, glucagon's effects, or both.
Cardiovascular Outcomes
Semaglutide's SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events. TRIUMPH-5 is examining whether retatrutide achieves comparable reduction. Early biomarker data from TRIUMPH-4—reductions in non-HDL cholesterol, CRP, triglycerides, and blood pressure—is consistent with the pattern observed before SELECT confirmed cardiovascular benefit.
Laboratory-Grade Metabolic Research Peptides
Every batch independently tested. HPLC verified. Suitable for in vitro research. No guessing on purity.
Get Pure Grade Research Peptides →Retatrutide UK Timeline: When Will It Be Available on Prescription?
Current status (May 2026): Retatrutide has not received MHRA, FDA, or EMA marketing authorisation. It cannot be legally prescribed or dispensed in the UK. It is accessible only within authorised clinical trials.
The estimated regulatory timeline:
- 2026: Remaining TRIUMPH trial primary endpoint data expected (TRIUMPH-1, 2, 3, 5, REDEFINE)
- Late 2026 to Q1 2027: Potential FDA New Drug Application submission by Eli Lilly, if Phase 3 data is satisfactory
- 2027-2028: Possible FDA approval (priority review could accelerate to mid-2027; standard review to 2028)
- MHRA approval typically follows FDA by 6-12 months
- 2028 onwards: Potential NHS availability, subject to NICE technology appraisal—a process that can add 12-24 months after MHRA approval
These timelines are estimates. The dysesthesia signal from TRIUMPH-4 will require explanation before regulators are satisfied. Anyone presenting retatrutide as imminent on UK prescriptions is not reading the timeline accurately.
Separate from the prescription medicine pathway, research-grade retatrutide is available in the UK as a research chemical for in vitro laboratory use—the same regulatory framework that applies to other investigational peptides.
Rachel runs a metabolic biology research unit in Bristol. She had been using semaglutide analogues as control compounds in in vitro receptor binding studies. When TRIUMPH-4 data came out, she wanted to add retatrutide to her receptor characterisation work—specifically to study glucagon receptor agonism in isolated adipocyte models. She sourced research-grade retatrutide with independent COA documentation. The compound she needed for in vitro work was available. The prescription medicine version wasn't. These are two completely separate tracks.
Frequently Asked Questions About Retatrutide
What makes retatrutide different from semaglutide and tirzepatide?
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GLP-1 + GIP. Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The glucagon component is the differentiator—it increases energy expenditure and drives hepatic fat oxidation, mechanisms neither semaglutide nor tirzepatide possess. Phase 3 data shows retatrutide produces 28.7% weight loss vs 22.5% for tirzepatide in separate trials.
Can I get retatrutide on the NHS or through a private prescription in the UK?
No. As of May 2026, retatrutide has not received MHRA Marketing Authorisation. It cannot be prescribed, dispensed, or legally obtained through NHS or licensed private prescribers in the UK. The earliest realistic timeline for prescription availability is 2028, assuming Phase 3 data is positive and NICE approval follows MHRA sign-off. Research-grade retatrutide is available separately under the research chemical framework for in vitro laboratory use.
What were the TRIUMPH-4 Phase 3 results?
TRIUMPH-4 enrolled 445 participants with obesity/overweight and knee osteoarthritis. At 68 weeks, the 12 mg dose of retatrutide produced 28.7% mean body weight reduction (approximately 32.3 kg)—the largest weight loss result in any obesity pharmacotherapy trial. A new safety signal emerged: dysesthesia in 8.8% at 9 mg and 20.9% at 12 mg, vs 0.7% on placebo. This signal requires further characterisation before regulatory submission.
How does retatrutide reduce liver fat more than semaglutide or tirzepatide?
The glucagon receptor component. Glucagon stimulates hepatic fat oxidation—the breakdown of stored fat in the liver. Phase 2a data published in Nature Medicine showed up to 82% liver fat reduction at 24 weeks on 12 mg retatrutide. This substantially exceeds what semaglutide achieves through weight loss alone. This mechanism positions retatrutide as potentially the first effective pharmacological treatment for MASH, which currently has no approved options.
What are the known side effects of retatrutide?
Phase 2 side effects match other GLP-1-containing therapies: nausea, vomiting, diarrhoea, and constipation—primarily during dose escalation, mostly mild-to-moderate, diminishing over time. TRIUMPH-4 identified a new signal not previously seen with semaglutide or tirzepatide: dysesthesia in 8.8-20.9% at higher doses. The mechanism and clinical significance are under investigation. Long-term safety data from the full Phase 3 programme is still being gathered.
Summary
Retatrutide is the most advanced triple hormone receptor agonist in clinical development for obesity and metabolic disease. Its mechanism—simultaneous GLP-1, GIP, and glucagon receptor activation—is pharmacologically distinct from every approved obesity medicine. The glucagon component drives energy expenditure and hepatic fat oxidation that GLP-1 and GIP pathways cannot replicate.
Phase 3 TRIUMPH-4 reported 28.7% weight loss at 68 weeks—the largest weight loss result ever recorded in obesity pharmacotherapy. Liver fat reduction of up to 82% in Phase 2a positions retatrutide as a potentially transformative treatment for MASH, where no approved option currently exists. The new dysesthesia signal in TRIUMPH-4 requires full characterisation before regulatory submission.
For the UK: prescription retatrutide is years away—realistic availability is 2028 at earliest, contingent on Phase 3 data, regulatory submissions, and NICE appraisal. Research-grade retatrutide is available now for in vitro laboratory use under the same research chemical framework.
References
- Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine, 389(6):514-526. DOI: 10.1056/NEJMoa2301972
- Rosenstock J et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, phase 2 trial. The Lancet, 402(10401):529-544
- Alkhouri N et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine. DOI: 10.1038/s41591-024-03018-2
- Eli Lilly and Company. (December 2025). Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial. Press release. investor.lilly.com
- Coskun T et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism, 34:1234-1247